Saturday, 17 October 2026European Markets

MOURY CONSTRUCT Stock Bullish Momentum With A 27% Rise In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of MOURY CONSTRUCT (BEL 20: MOUR.BR) jumped by a staggering 27.59% in 21 sessions from €289.99 to €370.00 at 20:21 EST on Wednesday, after three consecutive sessions in a row of losses. BEL 20 is rising 0.19% to €3,838.40, following the last session's downward trend.

MOURY CONSTRUCT's last close was €370.00, 3.65% under its 52-week high of €384.00.

About MOURY CONSTRUCT

Moury Construct SA engages in the construction and renovation of residential and non-residential buildings for private and public markets in Belgium. The company undertakes public and private buildings, commercial areas, halls of structures, renovation and restoration, and industries and services projects. It is also involved in the general joinery, and thermal and acoustic insulations; prefabrication of concrete elements; and promotion and real estate arrangements. The company was founded in 1920 and is based in Liège, Belgium.

Earnings Per Share

As for profitability, MOURY CONSTRUCT has a trailing twelve months EPS of €37.01.

PE Ratio

MOURY CONSTRUCT has a trailing twelve months price to earnings ratio of 10. Meaning, the purchaser of the share is investing €10 for every euro of annual earnings.

More news about MOURY CONSTRUCT (MOUR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com